Company Description
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally.
The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.
It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol.
Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Country | Switzerland |
| Founded | 1895 |
| IPO Date | Nov 18, 1991 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,883 |
| CEO | Vasant Narasimhan |
Contact Details
Address: Lichtstrasse 35 Basel, 4056 Switzerland | |
| Phone | 41 61 324 11 11 |
| Website | novartis.com |
Stock Details
| Ticker Symbol | NVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001114448 |
| CUSIP Number | 66987V109 |
| ISIN Number | US66987V1098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer |
| Harry Kirsch | Chief Financial Officer |
| Victor Bulto | President of US |
| Dr. Patrick Horber M.D. | President of International |
| Dr. Steffen Lang Ph.D. | President of Operations |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Sloan Simpson | Global Head of Investor Relations |
| Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk and Compliance Officer |
| Karen L. Hale | Chief Legal Officer |
| Dr. Robert Kowalski Pharm.D. | Chief People and Organization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 31, 2025 | 6-K | Report of foreign issuer |
| Jan 31, 2025 | 6-K | Report of foreign issuer |
| Jan 31, 2025 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Jan 31, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Dec 30, 2024 | 6-K | Report of foreign issuer |
| Nov 25, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | 6-K | Report of foreign issuer |
| Sep 18, 2024 | 6-K | Report of foreign issuer |
| Sep 17, 2024 | 424B5 | Filing |